학술논문

927P Patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with nivolumab (NIVO) in the first-line (1L) or later-line (2L+) settings in Germany: Updated results from the real-world HANNA study
Document Type
Abstract
Source
In Annals of Oncology October 2023 34 Supplement 2:S584-S585
Subject
Language
ISSN
0923-7534